Cancer drug holds promise for shrinking polycystic kidney cysts
Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease, can lead to kidney enlargement and eventual loss of function.
Stay updated with breaking news from John Essigmann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease, can lead to kidney enlargement and eventual loss of function.
A compound originally developed as a cancer treatment may hold promise for treating polycystic kidney disease (ADPKD), which affects more than half a million Americans and can lead to kidney enlargement and loss of function.
ADPKD, the prevalent form of polycystic kidney disease, causes kidney enlargement, often leading to function loss.
ADPKD, the prevalent form of polycystic kidney disease, causes kidney enlargement, often leading to function loss.
E-Mail CAMBRIDGE, MA -- In the past few years, several medications have been found to be contaminated with NDMA, a probable carcinogen. This chemical, which has also been found at Superfund sites and in some cases has spread to drinking water supplies, causes DNA damage that can lead to cancer. MIT researchers have now discovered a mechanism that helps explain whether this damage will lead to cancer in mice: The key is the way cellular DNA repair systems respond. The team found that too little activity of one enzyme necessary for DNA repair leads to much higher cancer rates, while too much ...